Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTanfield Regulatory News (TAN)

Share Price Information for Tanfield (TAN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.60
Bid: 3.60
Ask: 4.14
Change: -0.29 (-7.46%)
Spread: 0.54 (15.00%)
Open: 3.60
High: 3.60
Low: 3.60
Prev. Close: 3.89
TAN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Loan Subscription & Legal Proceedings Update

26 Jan 2021 13:39

RNS Number : 9513M
Tanfield Group PLC
26 January 2021
 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain

 

 

Tanfield Group Plc

("Tanfield" or the "Company")

 

Loan Subscription & Legal Proceedings Update

 

 

Background

 

· Tanfield is a 49% shareholder in the equity of Snorkel International Holdings LLC ("Snorkel") following the joint venture between the Company and Xtreme Manufacturing LLC ("Xtreme") (the "Contemplated Transaction"), a company owned by Don Ahern of Ahern Rentals Inc, relating to Snorkel, in October 2013.

 

· The Snorkel investment is valued at £19.1m. The outcome of the US and UK Proceedings referenced below could have an impact on this valuation.

 

· On 22 October 2019, the Company announced that it had received a Summons and Complaint, filed in Nevada by subsidiaries of Xtreme, relating to the Contemplated Transaction (the "US Proceedings").

 

· On 24 October 2019, the Company announced it had become necessary to issue and serve a claim in the English High Court against Ward Hadaway (the "UK Proceedings"), the solicitor acting for the Company at the time of the Contemplated Transaction, in order to fully protect the Company's rights pending the outcome of the US Proceedings.

 

Loan Subscription

 

Further to the update on 30 July 2020, in which the Company announced that it had put in place a second loan note instrument (the "Loan") of up to £1m with £500,000 initially being subscribed to, the Board of Tanfield (the "Board") is pleased to announce that an additional £200,000 of the Loan has been subscribed to, taking the total subscription value to £700,000. The additional Loan will be used for the purpose of providing the necessary funding for the ongoing US and UK Proceedings and other day to day costs.

 

The additional Loan is unsecured, carries annual interest of 10% which is to accrue and is repayable on the earlier of (i) 28 February 2025 or (ii) receipt of sufficient funds relating to either the US Proceedings or the UK Proceedings. Should repayment take place prior to 28 February 2025, a 20% early redemption premium shall apply.

 

A number of existing shareholders have subscribed to the additional Loan of £200,000, which constitutes a related party transaction under Rule 13 of the AIM Rules as a result of OTK Holding A/S and Zoar Invest Aps, which each hold approximately 14% of the issued shares of the Company, subscribing £75,000 each to the Loan. The Directors of the Company, having consulted with WH Ireland Limited, the Company's nominated adviser, consider the terms of the transaction to be fair and reasonable.

 

Following discussions with the existing shareholders, the Board are of the opinion that further subscriptions to the Loan will take place as necessary to ensure the Company can continue to protect its investment in Snorkel.

 

US Proceedings

 

On 22 October 2019, the Company announced it had received a Summons and Complaint in relation to the US Proceedings, regarding the purported call option notice announced by the Company in November 2018. As reported, despite the Board seeking to resolve the dispute amicably, Snorkel and Xtreme, by filing the Summons and Complaint, continued in their attempt to take ownership of Tanfield's 49% investment in Snorkel for an overall nil consideration, having not paid any consideration to Tanfield for Xtreme's initial 51% of the joint venture and purporting that no consideration is due to Tanfield before it can compel the Company to transfer its remaining 49% investment to Snorkel / Xtreme. The Board notes that Snorkel / Xtreme make this claim despite declaring in various K-1 US tax declarations that Tanfield, via its subsidiary HBWP Inc, contributed properties with a net fair market value of $45,476,730 to Snorkel International Holdings LLC in October 2013. The Board continues to believe that the contractual agreements require that the preferred interest (valued at £19.1m) is paid prior to, or in conjunction with, a call option notice.

 

On 30 March 2020, the Company announced that despite ongoing attempts to resolve the dispute amicably, Snorkel and Xtreme filed a motion in favour of their claims and against claims brought by Tanfield, without a trial, claiming that there were no genuine issues of material fact (the "Motion"). The Board vehemently disagreed with the Motion and believed that it was without merit and subsequently, on 3 April 2020, the Company announced that the judge took the Motion under advisement and, after a review and consideration of the record and the contract, the court determined that there appears to be genuine issues of material fact pertaining to the contract, its terms, and its execution and therefore the Motion brought by Snorkel and Xtreme was denied.

 

The parties have been producing documents as part of the ongoing discovery process. Despite the Board's best efforts to keep procedural matters to the agreed timetable, there have been delays relating to any meaningful productions of documents by Snorkel / Xtreme. However, the Board is pleased to update that some progress has now been made and, following exchanges between respective counsels, further documents have recently been produced, as well as assurances given that further document productions will soon be forthcoming. Whilst document production is still ongoing, as a result of the assurances received, the Board are hopeful that the proceedings will soon proceed to the taking of depositions from those involved in the Contemplated Transaction. The matter is currently expected to continue to trial later in the year.

 

UK Proceedings

 

On 24 October 2019, the Company also announced it was necessary to issue and serve a claim in the English High Court against Ward Hadaway, the solicitor acting for the Company in 2013, in order to fully protect the Company's rights pending the outcome of the US Proceedings. Those proceedings seek to ensure that the Company can, if necessary, hold Ward Hadaway to account for the firm's role in and/or advice to Tanfield in relation to the Contemplated Transaction.

 

Whilst the Board vehemently deny the claims made by Snorkel and Xtreme in the US Proceedings, a major part of the UK Proceedings is premised on the Company losing the US Proceedings. If that were to happen, the UK Proceedings are, in summary, that Ward Hadaway were retained to advise and assist the Company in connection with the Contemplated Transaction, in particular the preparation of the Circular and the process of obtaining the required Shareholder and Board approval before the Contemplated Transaction could be entered into, and that the firm was negligent and/or acted in breach of contract in carrying out that role, the result of which has led to the Company suffering substantial financial loss.

 

The parties recently agreed to amend their respective statements of case and are currently working towards a trial later in the year. One of the steps in the court timetable is the preparation of expert forensic accountancy evidence which seeks to value the Snorkel division and assets which were contributed to the joint venture as part of the Contemplated Transaction. The Board believe that value to have been substantial.

 

 

The Board remain hopeful that a positive outcome to either/both the US Proceedings and UK Proceedings is possible and, so far as it is necessary, the Company will continue to vigorously defend and advance its position in both proceedings, whilst continuing to seek advice. Further updates will be provided to Shareholders as and when appropriate.

 

 

 

 

For further information:

 

Tanfield Group Plc 020 7220 1666

Daryn Robinson  

 

WH Ireland Limited - Nominated Advisor / Broker

James Joyce / Lydia Zychowska 020 7220 1666

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKABNNBKDADB
Date   Source Headline
29th Apr 20084:25 pmRNSHolding(s) in Company
28th Apr 20082:57 pmRNSExercise of options
28th Apr 20082:51 pmRNSHolding(s) in Company
22nd Apr 20087:01 amRNSFinal Results
15th Apr 20087:00 amRNSNew product launch
19th Mar 200811:38 amRNSNotice of Results
14th Mar 200812:53 pmRNSHolding(s) in Company
14th Mar 200812:51 pmRNSHolding(s) in Company
12th Mar 20084:32 pmRNSHolding(s) in Company
7th Mar 20089:30 amRNSHolding(s) in Company
29th Feb 200811:21 amRNSHolding(s) in Company
28th Feb 20082:48 pmRNSHolding(s) in Company
25th Feb 20083:05 pmRNSHolding(s) in Company
25th Feb 20087:01 amRNSEnova Confirms Order
11th Feb 20089:25 amRNSHolding(s) in Company
14th Jan 20087:00 amRNSStmnt re Share Price Movement
9th Jan 20083:54 pmRNSHolding(s) in Company
18th Dec 20077:01 amRNSPre-Close Trading Update
11th Dec 200710:45 amRNSHolding(s) in Company
28th Nov 200712:59 pmRNSHolding(s) in Company
21st Nov 20071:02 pmRNSHolding(s) in Company
16th Nov 200710:29 amRNSHolding(s) in Company
8th Nov 200710:40 amRNSHolding(s) in Company
6th Nov 200710:04 amRNSHolding(s) in Company
26th Oct 200711:56 amRNSHolding(s) in Company
10th Oct 200711:07 amRNSHolding(s) in Company
8th Oct 200711:53 amRNSHolding(s) in Company
1st Oct 20072:10 pmRNSResult of AGM
25th Sep 20077:03 amRNSInterim Results
4th Sep 20075:36 pmRNSHolding(s) in Company
23rd Aug 200712:06 pmRNSHolding(s) in Company
16th Aug 20077:00 amRNSNotice of Interim Results
15th Aug 20073:28 pmRNSAIM Rule 26
10th Aug 20075:31 pmRNSHolding(s) in Company
6th Aug 200710:04 amRNSHolding(s) in Company
1st Aug 20079:01 amRNSAcquisition Completion
31st Jul 20071:09 pmRNSHolding(s) in Company
26th Jul 20077:01 amRNSAcquisition Update
23rd Jul 200712:15 pmRNSTrading Statement
23rd Jul 200712:15 pmRNSEGM Statement
17th Jul 20072:06 pmRNSHolding(s) in Company
9th Jul 20074:03 pmRNSHolding(s) in Company
28th Jun 20072:43 pmRNSHolding(s) in Company
28th Jun 20079:26 amRNSAnnual Report and Accounts
28th Jun 20077:04 amRNSAcquisition & Placing
27th Jun 200711:17 amRNSRe: Press Speculation
21st Jun 20072:19 pmRNSHolding(s) in Company
20th Jun 20077:02 amRNSEnova Confirms Order
13th Jun 20077:01 amRNSContract Win
7th Jun 200710:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.